Health care cost growth among the privately insured
- PMID: 19738244
- DOI: 10.1377/hlthaff.28.5.1294
Health care cost growth among the privately insured
Erratum in
- Health Aff (Millwood). 2010 Jan-Feb;29(1):223
Abstract
Controlling health care cost growth remains a high priority for policymakers and private decisionmakers, yet little is known about sources of this growth. We examined spending growth among the privately insured between 2001 and 2006, separating the contributions of price changes from those driven by consumption. Most spending growth was driven by outpatient services and pharmaceuticals, with growth in quantities explaining the entire growth in outpatient spending and about three-quarters of growth in spending on prescription drugs. Rising prices played a greater role in growth in spending for brand-name than for generic drugs. These findings can inform efforts to control private- sector spending.
Similar articles
-
Does public insurance provide better financial protection against rising health care costs for families of children with special health care needs?Med Care. 2008 Oct;46(10):1064-70. doi: 10.1097/MLR.0b013e318185cdf2. Med Care. 2008. PMID: 18815528
-
Measuring adequacy of coverage for the privately insured: new state estimates to monitor trends in health insurance coverage.Med Care Res Rev. 2009 Apr;66(2):167-80. doi: 10.1177/1077558708330426. Epub 2009 Jan 16. Med Care Res Rev. 2009. PMID: 19151260
-
Impact of cost sharing on prescription drugs used by Medicare beneficiaries.Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7. Res Social Adm Pharm. 2010. PMID: 20511109
-
Containing U.S. health care costs: what bullet to bite?Health Care Financ Rev Annu Suppl. 1991:1-12. Health Care Financ Rev Annu Suppl. 1991. PMID: 10117114 Review.
-
The rising cost of diabetes care in the USA.Lancet Diabetes Endocrinol. 2016 Jun;4(6):479-80. doi: 10.1016/S2213-8587(15)00519-7. Epub 2016 May 4. Lancet Diabetes Endocrinol. 2016. PMID: 27156052 Free PMC article. Review. No abstract available.
Cited by
-
Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation.PLoS One. 2024 May 2;19(5):e0301716. doi: 10.1371/journal.pone.0301716. eCollection 2024. PLoS One. 2024. PMID: 38696520 Free PMC article.
-
Unintended consequences of healthcare reform in South Korea: evidence from a regression discontinuity in time design.Health Res Policy Syst. 2023 Jun 22;21(1):60. doi: 10.1186/s12961-023-00993-9. Health Res Policy Syst. 2023. PMID: 37349727 Free PMC article.
-
On the Anatomy of Medical Progress Within an Overlapping Generations Economy.Economist (Leiden). 2020;168(2):215-257. doi: 10.1007/s10645-020-09360-3. Epub 2020 Apr 6. Economist (Leiden). 2020. PMID: 32624586 Free PMC article.
-
Jeffrey's insights: Jeffrey Modell Foundation's global genetic sequencing pilot program to identify specific primary immunodeficiency defects to optimize disease management and treatment.Immunol Res. 2020 Jun;68(3):126-134. doi: 10.1007/s12026-020-09131-x. Immunol Res. 2020. PMID: 32462469 Free PMC article.
-
Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.Arthritis Rheumatol. 2020 Feb;72(2):234-241. doi: 10.1002/art.41138. Epub 2020 Jan 6. Arthritis Rheumatol. 2020. PMID: 31609057 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
